650 East Kendall Street
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1449 articles about Takeda
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. (JOBS) Phase 2 Data of Investigational Drug, Hematide, Suggest Its Ability to Restore Hemoglobin in Patients With Pure Red Cell Aplasia
Takeda Pharmaceuticals North America, Inc. (JOBS) Establishes Takeda Pharmaceuticals Mexico, S.A. de C.V. Expanding Presence in North America
Amylin Pharmaceuticals, Inc. (JOBS) Strikes $1 Billion Deal with Takeda Pharmaceutical Co. Ltd. (JOBS) to Co-Develop Weight Loss Drugs
Takeda Pharmaceutical Co. Ltd. (JOBS) Holds Forecast, Drugs Outlook Still Tough
Takeda Pharmaceutical Co. Ltd.: New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults With Non-Erosive GERD
Takeda Pharmaceuticals North America, Inc.: ULORIC(R) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
Takeda Pharmaceuticals North America, Inc.'s Uloric (Febuxostat) Demonstrated Efficacy For Management Of Hyperuricemia In Patients With Gout, University of Chicago Study
Takeda San Diego's Vice President to Present at Upcoming Symposium
Takeda Pharmaceutical Co. Ltd.: New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
Takeda San Francisco Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Takeda Pharmaceutical Co. Ltd. (JOBS) to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
Takeda San Francisco Enters Into A Sponsored Research Agreement With University of California, San Francisco (UCSF)
Millennium: The Takeda Oncology Company Initiates Phase II Trial of Prostate Cancer Compound
Takeda Pharmaceutical Co. Ltd. Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Takeda Pharmaceutical Co. Ltd. (JOBS) to Start Key Diabetes Drug Trial in September
Chemizon Inc. Announces Further Expansion of Its Collaboration with Takeda Pharmaceutical Co. Ltd.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. (JOBS) Bowel Drug Lubiprostone Produces Mixed Results In Studies
FDA Extends Takeda Pharmaceutical Co. Ltd.'s (JOBS) Alogliptin-Actos Drug Review
Takeda Pharmaceutical Co. Ltd., Millennium: The Takeda Oncology Company And Canbas Co., Ltd.: CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
Takeda Pharmaceutical Co. Ltd. Fails to Get U.S. Approval for Diabetes Drug